Skip to main content

Table 1 Patient characteristics (n = 14)

From: Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis

Baseline characteristics
 Gleason score, n (%)
  ≤7 1 (7)
  8 6 (43)
  9 6 (43)
  10 1 (7)
 Prior local treatment, n (%) 3 (21)
  Radical prostatectomy, n 1
  Radical radiation therapy, n 2
Patient characteristics at initiation of enzalutamide
 Median age, years (range) 78 (50–88)
 Median time from CRPC to initiation of enzalutamide, mo (range) 5.1 (1.3–75.4)
 ECOG PS, n (%)
  0 5 (36)
  1 6 (43)
  2 3 (21)
  ≥3 0
 Number of previous vintage hormone manipulations, median (range) 3 (2–7)
 Metastatic site, n (%)
  Bone 13 (100)
   EOD1 1 (7)
   EOD2 7 (50)
   EOD3 6 (43)
   EOD4 0
  Lymph node 6 (43)
  Lung 1 (7)
  Liver 1 (7)
 PSA (ng/ml), median (range) 89.9 (22.4–445.6)
 Hemoglobin (g/l), median (range) 11.4 (9.7–14.0)
 LDH (U/l), median (range) 254 (173–2028)
 ALP (U/l), median (range) 205 (99–1303)
Patient characteristics at time of initiation of abiraterone acetate
 Median time from enzalutamide discontinuation to initiation of abiraterone acetate, day (range) 1 (1–69)
 ECOG PS, n (%)
  0 3 (21)
  1 5 (36)
  2 6 (43)
  ≥3 0
 PSA (ng/ml), median (range) 38.0 (8.6–572.1)
 Hemoglobin (g/l), median (range) 11.8 (9.2–14.0)
 LDH (U/l), median (range) 202 (143–960)
 ALP (U/l), median (range) 316 (117–717)